At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 517 enrolled
Drug / intervention
mil60 +1 moredrug
Likely dose
mil60 15mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of First-line mil60 Plus Paclitaxel/Carboplatin Versus Bevacizumab Plus Paclitaxel/Carboplatin in Patients With Advanced and Recurrent Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Phase 3 Study
In Brief
A Phase 3 clinical trial evaluating mil60 and Bevacizumab for Non-small Cell Lung Cancer. Completed, enrolled 517 participants across 2 sites.
Detailed Summary
This randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy and safety of mil60 with bevacizumab as first-line treatment when combined with standard chemotherapy (paclitaxel/carboplatin) in treatment-naive patients with advanced or recurrent non-squamous NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
CollaboratorsBetta Pharmaceuticals Co., Ltd.
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartAug 2017
Primary CompletionAug 2019
Study CompletionJul 2021
TodayJul 2026
First PostedJun 23, 2017
Enrollment StartAug 15, 2017
Primary CompletionAug 1, 2019
Study CompletionJul 30, 2021
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 9.0 years ago
Interventions
mil60drug
15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
Bevacizumabdrug
15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg